Short-term Effects of Transdermal Estradiol on Female COVID-19 Patients
COVID-19, Hormone Replacement Therapy
About this trial
This is an interventional treatment trial for COVID-19 focused on measuring Covid-19, hormone replacement therapy
Eligibility Criteria
Inclusion Criteria: Female patients diagnosed with Covid-19 disease Postmenopausal women (who had 12 months of amenorrhea after their final menstrual period) Positive reverse transcription-polymerase chain reaction (RT-PCR) test given with nasal and oral swabs Exclusion Criteria: Negative RT-PCR test Female patients at reproductive stage
Sites / Locations
- Istanbul University-Cerrahpasa
Arms of the Study
Arm 1
Arm 2
Experimental
Placebo Comparator
Experimental
Placebo
All patients were treated with favipiravir for a week. At the same time, the patients in this arm received Estradiol patch (Climara 7.8 mg patch/week, Bayer, Germany) for 14 days.
All patients were treated with favipiravir for a week. At the same time, the patients in this arm received Hydrogel patch (Adhesive Hydrogel patch/week, Rebul Pharmacy, Turkey) for 14 days.